Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

Open access
Lee, Keun Seok, Chung, Hyun Cheol, Im, Seock Ah, Park, Yeon Hee, Kim, Chul Soo, Kim, Sung-Bae, Rha, Sun Young, Lee, Min Young, Ro, Jungsil · 2008 · Breast Cancer Research and Treatment

Abstract

Genexol-PM is a novel Cremophor EL-free polymeric micelle formulation of paclitaxel. This single arm, multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM in patients with histologically confirmed metastatic breast cancer (MBC). Forty-one women received Genexol-PM by intravenous infusion at 300 mg/m2 over 3 h every 3 weeks without premedication until disease progression or intolerability. A total of 331 chemotherapy cycles were administered, with a median of 8 cycles per patient (range, 1-16). Overall response rate was 58.5% (95% CI: 43.5-72.3) with 5 complete responses and 19 partial responses. Thirty-seven patients who received Genexol-PM as a first-line therapy for their metastatic disease showed a response rate of 59.5% (95% CI: 43.5-73.7), and two responses were reported in four patients treated in the second-line setting for their metastatic disease. The median time to progression (TTP) for all patients was 9.0 months (range, 1.0-17.0+ months). Grade 3 non-hematologic toxicities included sensory peripheral neuropathy (51.2%), and myalgia (2.4%). Eight patients (19.5%) experienced hypersensitivity reactions, with grade 3 in two patients. Hematologic toxicities were grade 3 and 4 neutropenia (51.2 and 17.1%, respectively), and grade 1 and 2 thrombocytopenia (22.0%). Notably, no febrile neutropenia was observed. Genexol-PM appears a promising new paclitaxel in view of significant efficacies. Further trials with different dosing schedules, durations of delivery, or in combination with other drugs are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9591-y

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35:1114–1117 · doi:10.1345/aph.10287

Cited by

See all 541

Metadata

Authors
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J.
Affiliations
  • Korean Cancer Study Group (KR)
  • Yonsei University (KR)
  • Seoul National University (KR)
  • Inha University (KR)
  • Asan Medical Center (KR)
  • Samyang Holdings (South Korea) (KR)
Corresponding author
Ro, Jungsil
Venue
Breast Cancer Research and Treatment
Published
2007-05-03
Volume
108
Issue
2
Pages
241-250
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2091796668
Cited by
541
References
34
Citations by year
2026: 14 · 2025: 16 · 2024: 29 · 2023: 22 · 2022: 29 · 2021: 35 · 2020: 37 · 2019: 28 · 2018: 36 · 2017: 31 · 2016: 43 · 2015: 40 · 2014: 45 · 2013: 35 · 2012: 28
FWCI
8.10
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Computer Modeling in Engineering & Sciences
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
paclitaxel, polymeric micelles, metastatic breast cancer, first-line chemotherapy, second-line chemotherapy, overall response rate, time to progression, peripheral neuropathy, neutropenia, hypersensitivity, drug toxicity
MeSH terms
Adult, Aged, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Chemistry, Pharmaceutical, Drug Administration Schedule, Drug Carriers, Drug Compounding, Female, Humans, Infusions, Intravenous, Korea, Micelles, Middle Aged, Neoplasm Metastasis, Polyethylene Glycols, Polymers, Time Factors, Treatment Outcome, Paclitaxel, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1007/s10549-007-9591-y
The paper
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008). Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-007-9591-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.